血管紧张素受体阻滞剂作为房颤心律控制的辅助治疗:厄贝沙坦-胺碘酮试验的结果。

Antonio H Madrid, Carlos Escobar, José María G Rebollo, Irene Marín, Enrique Bernal, Sebastián Nannini, Lilianna Limón, Jian Peng, Concepción Moro
{"title":"血管紧张素受体阻滞剂作为房颤心律控制的辅助治疗:厄贝沙坦-胺碘酮试验的结果。","authors":"Antonio H Madrid,&nbsp;Carlos Escobar,&nbsp;José María G Rebollo,&nbsp;Irene Marín,&nbsp;Enrique Bernal,&nbsp;Sebastián Nannini,&nbsp;Lilianna Limón,&nbsp;Jian Peng,&nbsp;Concepción Moro","doi":"10.1023/B:CEPR.0000012391.95928.d2","DOIUrl":null,"url":null,"abstract":"<p><p>Atrial fibrillation (AF) is a common arrhythmia associated with increased risk of stroke and mortality. The early appearance of electrical remodeling is followed by structural remodeling of the atrial tissue. Direct current cardioversion of persistent AF is the most effective treatment for the restoration of sinus rhythm, but it is hampered by a high percentage of recurrences. Recurrences may be the consequence of both electrical and structural remodeling. A study on the use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent AF showed that this angiotensin II receptor blocker combined with amiodarone prolonged sinus rhythm after cardioversion. Irbesartan may have antifibrotic effects due not only to the ability to diminish the synthesis of collagen type I molecules but also to its capacity to stimulate the degradation of collagen type I fibers, as has been demonstrated with losartan, another angiotensin II receptor blocker. This suggests that efforts to reduce the structural changes that occur during AF may be more useful in preventing recurrences than efforts designed to minimize the electrical changes alone. The AFFIRM trial compared two approaches to the treatment of AF: cardioversion with antiarrhythmic drugs to maintain sinus rhythm and the use of rate-controlling drugs. The results show that management of AF with the rhythm-control strategy offers no survival advantage over the rate-control strategy. However, non-antiarrhythmic drugs to prevent recurrences, like irbesartan, were not controlled and amiodarone was used in a low percentage of the patients. The treatment strategies proposed in both AFFIRM and RACE, in our opinion, may not be the optimal. The modern clinical approach to AF involves an early intervention to restore sinus rhythm, therefore preventing atrial remodeling. The pretreatment of patients with AF who undergo electrical cardioversion is very important and will be the subject for continuous improvement.</p>","PeriodicalId":80888,"journal":{"name":"Cardiac electrophysiology review","volume":"7 3","pages":"243-6"},"PeriodicalIF":0.0000,"publicationDate":"2003-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1023/B:CEPR.0000012391.95928.d2","citationCount":"20","resultStr":"{\"title\":\"Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.\",\"authors\":\"Antonio H Madrid,&nbsp;Carlos Escobar,&nbsp;José María G Rebollo,&nbsp;Irene Marín,&nbsp;Enrique Bernal,&nbsp;Sebastián Nannini,&nbsp;Lilianna Limón,&nbsp;Jian Peng,&nbsp;Concepción Moro\",\"doi\":\"10.1023/B:CEPR.0000012391.95928.d2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Atrial fibrillation (AF) is a common arrhythmia associated with increased risk of stroke and mortality. The early appearance of electrical remodeling is followed by structural remodeling of the atrial tissue. Direct current cardioversion of persistent AF is the most effective treatment for the restoration of sinus rhythm, but it is hampered by a high percentage of recurrences. Recurrences may be the consequence of both electrical and structural remodeling. A study on the use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent AF showed that this angiotensin II receptor blocker combined with amiodarone prolonged sinus rhythm after cardioversion. Irbesartan may have antifibrotic effects due not only to the ability to diminish the synthesis of collagen type I molecules but also to its capacity to stimulate the degradation of collagen type I fibers, as has been demonstrated with losartan, another angiotensin II receptor blocker. This suggests that efforts to reduce the structural changes that occur during AF may be more useful in preventing recurrences than efforts designed to minimize the electrical changes alone. The AFFIRM trial compared two approaches to the treatment of AF: cardioversion with antiarrhythmic drugs to maintain sinus rhythm and the use of rate-controlling drugs. The results show that management of AF with the rhythm-control strategy offers no survival advantage over the rate-control strategy. However, non-antiarrhythmic drugs to prevent recurrences, like irbesartan, were not controlled and amiodarone was used in a low percentage of the patients. The treatment strategies proposed in both AFFIRM and RACE, in our opinion, may not be the optimal. The modern clinical approach to AF involves an early intervention to restore sinus rhythm, therefore preventing atrial remodeling. The pretreatment of patients with AF who undergo electrical cardioversion is very important and will be the subject for continuous improvement.</p>\",\"PeriodicalId\":80888,\"journal\":{\"name\":\"Cardiac electrophysiology review\",\"volume\":\"7 3\",\"pages\":\"243-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2003-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1023/B:CEPR.0000012391.95928.d2\",\"citationCount\":\"20\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiac electrophysiology review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1023/B:CEPR.0000012391.95928.d2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiac electrophysiology review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1023/B:CEPR.0000012391.95928.d2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 20

摘要

心房颤动(AF)是一种常见的心律失常,与卒中和死亡风险增加有关。电重构的早期表现是心房组织的结构重构。持续性房颤的直流电复律是恢复窦性心律最有效的治疗方法,但其复发率较高。复发可能是电和结构重塑的结果。一项使用厄贝沙坦维持长期持续性房颤患者窦性心律的研究表明,这种血管紧张素II受体阻滞剂联合胺碘酮可延长心律转复后的窦性心律。厄贝沙坦可能具有抗纤维化作用,这不仅是因为它能够减少I型胶原分子的合成,还因为它能够刺激I型胶原纤维的降解,正如氯沙坦(另一种血管紧张素II受体阻滞剂)所证明的那样。这表明,减少房颤期间发生的结构变化可能比减少单独的电变化更有助于预防房颤复发。AFFIRM试验比较了治疗房颤的两种方法:使用抗心律失常药物进行心律转复以维持窦性心律,以及使用心率控制药物。结果表明,心律控制策略与心率控制策略相比,没有生存优势。然而,预防复发的非抗心律失常药物,如厄贝沙坦,没有得到控制,胺碘酮在低比例的患者中使用。在我们看来,AFFIRM和RACE提出的治疗策略可能不是最佳的。房颤的现代临床方法包括早期干预以恢复窦性心律,从而防止心房重构。房颤患者电转复后的预处理是非常重要的,将是持续改善的课题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.

Atrial fibrillation (AF) is a common arrhythmia associated with increased risk of stroke and mortality. The early appearance of electrical remodeling is followed by structural remodeling of the atrial tissue. Direct current cardioversion of persistent AF is the most effective treatment for the restoration of sinus rhythm, but it is hampered by a high percentage of recurrences. Recurrences may be the consequence of both electrical and structural remodeling. A study on the use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent AF showed that this angiotensin II receptor blocker combined with amiodarone prolonged sinus rhythm after cardioversion. Irbesartan may have antifibrotic effects due not only to the ability to diminish the synthesis of collagen type I molecules but also to its capacity to stimulate the degradation of collagen type I fibers, as has been demonstrated with losartan, another angiotensin II receptor blocker. This suggests that efforts to reduce the structural changes that occur during AF may be more useful in preventing recurrences than efforts designed to minimize the electrical changes alone. The AFFIRM trial compared two approaches to the treatment of AF: cardioversion with antiarrhythmic drugs to maintain sinus rhythm and the use of rate-controlling drugs. The results show that management of AF with the rhythm-control strategy offers no survival advantage over the rate-control strategy. However, non-antiarrhythmic drugs to prevent recurrences, like irbesartan, were not controlled and amiodarone was used in a low percentage of the patients. The treatment strategies proposed in both AFFIRM and RACE, in our opinion, may not be the optimal. The modern clinical approach to AF involves an early intervention to restore sinus rhythm, therefore preventing atrial remodeling. The pretreatment of patients with AF who undergo electrical cardioversion is very important and will be the subject for continuous improvement.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信